Targeted therapy of BRAFmut melanoma induces significant responses in the majority of patients, and the MEK inhibitors combined with RAF/ERK/PI3K inhibitors enhance clinical efficacy for NRASmut melanoma, while the DOR is often short‐term (NEMO trial: mPFS = 2.8 months; NCT05217303: mPFS = 4.2 months) [158, 169]. This evidence concerns the gene MAP2K7 and melanoma.